ERBB2 and breast cancer: The specific aim of this project was biomolecular engineering of molecules capable of redirecting, accelerating, and amplifying immunity from the preventive immunity, attained due to HBsAg vaccination against hepatitis B viruses, towards the therapeutic immunity against HER-2+ breast cancers.